Genetic/JJ
Association/NN
Analysis/NN
of/IN
Fasting/JJ
and/CC
1-/CD
and/CC
2-Hour/JJ
Glucose/NN
Tolerance/NN
Test/JJS
Data/NNS
Using/VBG
a/DT
Generalized/JJ
Index/NN
of/IN
Dissimilarity/NN
Measure/NN
for/IN
the/DT
Korean/JJ
Population/NN
./.
====================
Glucose/NN
tolerance/NN
tests/NNS
have/VBP
been/VBN
devised/VBN
to/TO
determine/VB
the/DT
speed/JJ
of/IN
blood/NN
glucose/NN
clearance/NN
./.
====================
Diabetes/NNS
is/VBZ
often/RB
tested/VBN
with/IN
the/DT
standard/JJ
oral/JJ
glucose/NN
tolerance/NN
test/NN
(/(
OGTT/NN
)/)
,/,
along/IN
with/IN
fasting/JJ
glucose/NN
level/NN
./.
====================
However/RB
,/,
no/DT
single/JJ
test/NN
may/MD
be/VB
sufficient/JJ
for/IN
the/DT
diagnosis/NN
,/,
and/CC
the/DT
World/NN
Health/NN
Organization/NN
(/(
WHO/NN
)/)
/International/JJ
Diabetes/NNS
Federation/NN
(/(
IDF/NN
)/)
has/VBZ
suggested/VBN
composite/JJ
criteria/NNS
./.
====================
Accordingly/RB
,/,
a/DT
single/JJ
multi-class/JJ
trait/VBP
was/VBD
constructed/VBN
with/IN
three/CD
of/IN
the/DT
fasting/JJ
phenotypes/NNS
and/CC
1-/CD
and/CC
2-hour/JJ
OGTT/NN
phenotypes/NNS
from/IN
the/DT
Korean/JJ
Association/NN
Resource/NN
(/(
KARE/NN
)/)
project/VBP
,/,
and/CC
the/DT
genetic/JJ
association/NN
was/VBD
investigated/VBN
./.
====================
All/DT
of/IN
the/DT
18/CD
possible/JJ
combinations/NNS
made/VBD
out/IN
of/IN
the/DT
3/CD
sets/NNS
of/IN
classification/NN
for/IN
the/DT
individual/JJ
phenotypes/NNS
were/VBD
taken/VBN
into/IN
our/PRP$
analysis/NN
./.
====================
These/DT
were/VBD
possible/JJ
due/JJ
to/TO
a/DT
method/NN
that/DT
was/VBD
recently/RB
developed/VBD
by/IN
us/PRP
for/IN
estimating/VBG
genomic/JJ
associations/NNS
using/VBG
a/DT
generalized/VBN
index/NN
of/IN
dissimilarity/NN
./.
====================
Eight/CD
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
that/WDT
were/VBD
found/VBN
to/TO
have/VB
the/DT
strongest/JJS
main/JJ
effect/NN
are/VBP
reported/VBN
with/IN
the/DT
corresponding/JJ
genes/NNS
./.
====================
Four/CD
of/IN
them/PRP
conform/VBP
to/TO
previous/JJ
reports/NNS
,/,
located/JJ
in/IN
the/DT
CDKAL1/NN
gene/NN
,/,
while/IN
the/DT
other/JJ
4/CD
SNPs/NNS
are/VBP
new/JJ
findings/NNS
./.
====================
Two-order/CD
interacting/VBG
SNP/NN
pairs/NNS
of/IN
are/VBP
also/RB
presented/VBN
./.
====================
One/CD
pair/NN
(/(
rs2328549/NN
and/CC
rs6486740/NN
)/)
has/VBZ
a/DT
prominent/JJ
association/NN
,/,
where/WRB
the/DT
two/CD
single-nucleotide/JJ
polymorphism/NN
locations/NNS
are/VBP
CDKAL1/NN
and/CC
GLT1D1/NN
./.
====================
The/DT
latter/JJ
has/VBZ
not/RB
been/VBN
found/VBN
to/TO
have/VB
a/DT
strong/JJ
main/JJ
effect/NN
./.
====================
New/NN
findings/NNS
may/MD
result/VB
from/IN
the/DT
proper/JJ
construction/NN
and/CC
analysis/NN
of/IN
a/DT
composite/JJ
trait/VBP
./.
====================
Genome-wide/NN
association/NN
studies/NNS
have/VBP
been/VBN
aiming/VBG
to/TO
find/VB
the/DT
association/NN
between/IN
a/DT
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
)/)
and/CC
complex/NN
traits/VBZ
./.
====================
It/PRP
started/VBD
as/IN
a/DT
single-locus/JJ
approach/NN
that/DT
tested/VBN
a/DT
single/JJ
SNP/NN
at/IN
a/DT
time/NN
and/CC
selected/VBN
the/DT
top/NN
SNPs/NNS
./.
====================
However/RB
,/,
it/PRP
has/VBZ
become/VBN
clearer/RB
that/DT
most/JJS
complex/NN
diseases/NNS
are/VBP
associated/VBN
with/IN
multiple/JJ
genes/NNS
and/CC
their/PRP$
interactions/NNS
./.
====================
Therefore/RB
,/,
a/DT
multi-locus/JJ
approach/NN
is/VBZ
now/RB
regarded/VBN
as/IN
a/DT
necessity/NN
[/(
12/CD
]/)
./.
====================
Multifactor/JJ
dimensionality/NN
reduction/NN
is/VBZ
one/CD
of/IN
the/DT
widely/RB
accepted/VBN
methods/NNS
for/IN
addressing/VBG
this/DT
issue/NN
[/(
3/CD
]/)
./.
====================
Meanwhile/DT
,/,
it/PRP
has/VBZ
been/VBN
customary/JJ
to/TO
categorize/VB
a/DT
phenotype/NN
into/IN
a/DT
binary/JJ
trait/VBP
to/TO
divide/JJ
the/DT
observed/VBN
outcomes/NNS
into/IN
either/CC
a/DT
case/NN
or/CC
control/JJ
(/(
affected-unaffected/VBN
)/)
./.
====================
However/RB
,/,
some/DT
diseases/NNS
,/,
such/JJ
as/IN
obesity/NN
,/,
are/VBP
to/TO
be/VB
classified/VBN
with/IN
several/JJ
levels/NNS
of/IN
affectedness/NN
[/(
4/CD
]/)
./.
====================
In/IN
that/DT
case/NN
,/,
it/PRP
would/MD
be/VB
appropriate/JJ
to/TO
perform/VB
a/DT
multi-class/JJ
phenotype/NN
analysis/NN
./.
====================
A/DT
disease/NN
,/,
such/JJ
as/IN
hypertension/NN
,/,
may/MD
not/RB
be/VB
fully/RB
characterized/VBN
by/IN
a/DT
single/JJ
phenotype/NN
but/CC
by/IN
2/CD
or/CC
more/RBR
observed/VBN
phenotypes/NNS
[/(
5/CD
]/)
./.
====================
Then/RB
,/,
a/DT
composite/JJ
phenotype/NN
should/MD
be/VB
constructed/VBN
and/CC
analyzed/VBD
with/IN
genomic/JJ
data/NNS
to/TO
estimate/VB
the/DT
genome-wide/NN
association/NN
of/IN
the/DT
particular/JJ
disease/NN
./.
====================
Because/IN
the/DT
individual/JJ
observables/NNS
should/MD
have/VBP
2/CD
or/CC
more/RBR
classes/NNS
,/,
a/DT
composite/JJ
phenotype/NN
would/MD
be/VB
a/DT
multi-class/JJ
trait/VBP
,/,
with/IN
an/DT
indefinite/JJ
number/NN
of/IN
classes/NNS
./.
====================
Combining/VBG
the/DT
2/CD
aspects/NNS
above/JJ
,/,
a/DT
genomic/JJ
association/NN
study/NN
needs/VBZ
a/DT
method/NN
that/DT
is/VBZ
able/JJ
to/TO
take/VB
gene-gene/NN
interactions/NNS
and/CC
multi-class/JJ
and/CC
multivariate/JJ
traits/VBZ
into/IN
consideration/NN
simultaneously/RB
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
will/MD
apply/RB
a/DT
recently/RB
introduced/VBN
generalized/VBN
index/NN
of/IN
dissimilarity/NN
(/(
GIDS/NN
)/)
[/(
5/CD
]/)
to/TO
demonstrate/VB
a/DT
multivariate/JJ
multi-class/JJ
trait/VBP
genomic/JJ
association/NN
study/NN
with/IN
diabetes/NNS
./.
====================
A/DT
composite/JJ
phenotype/NN
with/IN
the/DT
complete/JJ
set/NN
of/IN
classes/NNS
,/,
which/WDT
was/VBD
constructed/VBN
with/IN
3/CD
individual/JJ
phenotypes/NNS
obtained/VBN
by/IN
measuring/VBG
the/DT
blood/NN
glucose/NN
levels/NNS
using/VBG
different/JJ
protocols/NNS
[/(
67/CD
]/)
,/,
was/VBD
analyzed/VBN
with/IN
genomic/JJ
data/NNS
to/TO
estimate/VB
the/DT
genome-wide/NN
association/NN
./.
====================
Gene-gene/NN
interactions/NNS
and/CC
the/DT
main/JJ
effect/NN
were/VBD
investigated/VBN
./.
====================
Among/IN
the/DT
strongly/RB
associated/VBN
SNPs/NNS
,/,
some/DT
were/VBD
found/VBN
to/TO
be/VB
consistent/JJ
with/IN
previous/JJ
results/NNS
,/,
while/IN
the/DT
rest/NN
of/IN
them/PRP
were/VBD
new/JJ
findings/NNS
./.
====================
SNP/NN
pairs/NNS
that/DT
were/VBD
found/VBN
to/TO
have/VB
a/DT
strong/JJ
association/NN
are/VBP
also/RB
presented/VBN
./.
====================
Index/NN
of/IN
dissimilarity/NN
as/IN
a/DT
measure/NN
of/IN
association/NN
====================
Introduced/JJ
originally/RB
as/IN
a/DT
segregation/NN
measure/VB
[/(
8/CD
]/)
,/,
the/DT
index/NN
of/IN
dissimilarity/NN
(/(
IDS/NN
)/)
has/VBZ
been/VBN
shown/VBN
to/TO
be/VB
effective/JJ
in/IN
measuring/VBG
genomic/JJ
associations/NNS
,/,
as/IN
well/RB
[/(
5/CD
]/)
./.
====================
A/DT
generalized/VBN
version/NN
of/IN
the/DT
IDS/NN
(/(
GIDS/NN
)/)
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
able/JJ
to/TO
yield/VB
the/DT
association/NN
strength/NN
with/IN
a/DT
phenotype/NN
having/VBG
an/DT
arbitrary/JJ
number/NN
of/IN
classes/NNS
[/(
5/CD
]/)
./.
====================
Fig/NN
./.
====================
1/CD
has/VBZ
the/DT
schematics/NNS
for/IN
the/DT
association/NN
of/IN
2-order/JJ
gene-gene/NN
interactions/NNS
with/IN
a/DT
J-class/JJ
phenotype/NN
./.
====================
GIDS/NN
is/VBZ
defined/VBN
as/IN
below/IN
following/VBG
the/DT
notation/NN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
G/NN
I/NN
D/NN
S/NN
=/JJ
1/CD
2/CD
∑/NNP
j/RB
=/JJ
1/CD
J/NN
∑/NNP
i/LS
n/NN
i/LS
j/RB
−/NNP
E/NN
i/LS
j/RB
∑/NNP
j/RB
=/JJ
1/CD
J/NN
n/NN
•/NNP
P/NN
•/NNP
j/RB
•/NNP
(/(
1/LS
−/NN
P/NN
•/NNP
j/RB
)/)
where/WRB
n/NN
=/JJ
∑/CD
j/RB
=/JJ
1/CD
J/NN
n/NN
•/NNP
j/RB
,/,
E/NNP
i/LS
j/RB
=/JJ
n/NN
j/RB
•/NNP
•/NNP
n/NN
•/NNP
j/RB
n/NN
,/,
P/NN
•/NNP
j/RB
=/JJ
n/NN
•/NNP
j/RB
n/NN
(/(
1/LS
)/)
====================
Indices/NNS
i/LS
and/CC
j/NN
represent/VBP
the/DT
ith/NN
multi-locus/JJ
genotype/NN
and/CC
the/DT
jth/NN
multi-class/JJ
phenotype/NN
,/,
respectively/RB
./.
====================
The/DT
numerator/NN
of/IN
this/DT
equation/NN
measures/NNS
the/DT
extent/NN
of/IN
uneven/JJ
distributions/NNS
by/IN
each/DT
phenotype/NN
class/NN
,/,
where/WRB
the/DT
denominator/NN
indicates/VBZ
the/DT
maximum/NN
possible/JJ
unevenness/IN
[/(
8/CD
]/)
./.
====================
To/TO
visualize/VB
this/DT
concept/NN
,/,
let/NN
us/PRP
reduce/VBP
GIDS/NN
to/TO
a/DT
binary—i.e./FW
,/,
J/NN
=/JJ
2/CD
,/,
class—as/NNS
shown/VBN
in/IN
Eq/NN
./.
====================
(/(
2/CD
)/)
./.
====================
G/NN
I/NN
D/NN
S/NNP
J/NNP
=/JJ
2/CD
=/JJ
1/CD
2/CD
∑/NNP
i/LS
n/NN
i/LS
1/CD
−/NNP
(/(
n/NN
i/LS
1/CD
+/CC
n/NN
i/LS
2/CD
)/)
n/NN
•/RB
1/CD
n/NN
+/CC
∑/NNP
i/LS
n/NN
i/LS
2/CD
−/NNP
(/(
n/NN
i/LS
1/CD
+/CC
n/NN
i/LS
2/CD
)/)
n/NN
•/RB
2/CD
n/NN
n/NN
•/RB
1/CD
(/(
1/LS
−/NNP
n/NN
•/RB
1/CD
n/NN
)/)
+/CC
n/NN
•/RB
2/CD
(/(
1/LS
−/NNP
n/NN
•/RB
2/CD
n/NN
)/)
=/JJ
1/CD
2/CD
∑/NNP
i/LS
n/NN
i/LS
1/CD
n/NN
•/RB
1/CD
−/NNP
n/NN
i/LS
2/CD
n/NN
•/RB
2/CD
(/(
2/CD
)/)
====================
When/WRB
there/EX
is/VBZ
little/JJ
association/NN
between/IN
the/DT
genotype/NN
and/CC
phenotype/NN
,/,
there/EX
would/MD
be/VB
a/DT
minimal/JJ
difference/NN
between/IN
the/DT
2/CD
fractional/JJ
terms/NNS
for/IN
each/DT
i/LS
./.
====================
Maximum/NN
association/NN
occurs/VBZ
when/WRB
the/DT
differences/NNS
for/IN
each/DT
i/LS
in/IN
this/DT
equation/NN
add/VBP
up/IN
to/TO
the/DT
maximum/NN
./.
====================
Estimation/NN
of/IN
the/DT
association/NN
strength/NN
====================
To/TO
estimate/VB
the/DT
association/NN
strength/NN
,/,
GIDS/NN
is/VBZ
calculated/VBN
using/VBG
Eq/JJ
./.
====================
(/(
1/CD
)/)
./.
====================
The/DT
number/NN
of/IN
samples/NNS
,/,
nij/RB
,/,
that/DT
goe/VBP
into/IN
the/DT
formula/NN
for/IN
GIDS/NN
is/VBZ
counted/VBN
using/VBG
a/DT
2-way/JJ
contingency/NN
table/JJ
,/,
constructed/VBN
for/IN
the/DT
k-locus/NN
interactive/JJ
genotype/NN
and/CC
J-class/NN
phenotype/NN
,/,
as/IN
diagrammed/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
The/DT
number/NN
of/IN
elements/NNS
of/IN
this/DT
table/JJ
will/MD
be/VB
3k/JJ
×/CD
J./NNP
GIDS/NN
would/MD
be/VB
calculated/VBN
exhaustively/RB
for/IN
every/RB
SNP/NN
or/CC
combination/NN
of/IN
SNPs/NNS
associated/VBN
with/IN
a/DT
multi-class/JJ
categorical/JJ
phenotype/NN
./.
====================
Any/DT
order/NN
of/IN
a/DT
gene-gene/JJ
interaction/NN
associated/VBN
with/IN
a/DT
phenotype/NN
of/IN
an/DT
arbitrary/JJ
number/NN
of/IN
categories/NNS
can/MD
be/VB
estimated/VBN
in/IN
theory/JJ
,/,
limited/JJ
only/RB
by/IN
computing/VBG
time/NN
./.
====================
GIDS/NN
spans/NNS
from/IN
0/CD
to/TO
1/CD
,/,
representing/VBG
null/JJ
and/CC
maximum/NN
association/NN
at/IN
either/CC
of/IN
the/DT
extremes/NNS
./.
====================
p-values/NNS
that/DT
account/VBP
for/IN
multiple/JJ
comparisons/NNS
can/MD
be/VB
obtained/VBN
by/IN
constructing/VBG
a/DT
null/JJ
distribution/NN
common/JJ
to/TO
all/DT
of/IN
the/DT
GIDS/NN
values/NNS
[/(
9/CD
]/)
./.
====================
Permutation/NN
of/IN
the/DT
dataset/NN
is/VBZ
performed/VBN
to/TO
provide/VB
a/DT
non-associated/JJ
dataset/NN
./.
====================
A/DT
single/JJ
GIDS/NN
that/DT
has/VBZ
the/DT
maximum/NN
value/NN
among/IN
all/DT
GIDS/NN
values/NNS
obtained/VBN
with/IN
a/DT
permuted/JJ
dataset/NN
is/VBZ
collected/VBN
./.
====================
Repeated/VBN
permutation/NN
and/CC
collection/NN
make/VBP
the/DT
null/JJ
distribution/NN
of/IN
GIDS/NN
./.
====================
Now/RB
,/,
a/DT
p-value/JJ
should/MD
be/VB
the/DT
probability/NN
that/DT
the/DT
null/JJ
distribution/NN
exceeds/VBZ
a/DT
particular/JJ
GIDS/NN
value/NN
./.
====================
Using/VBG
this/DT
null/JJ
distribution/NN
,/,
GIDS/NN
can/MD
be/VB
standardized/VBN
as/IN
follows/VBZ
,/,
where/WRB
GIDS¯/NN
and/CC
SGIDS/NN
represent/VBP
the/DT
mean/JJ
and/CC
standard/JJ
deviation/NN
of/IN
the/DT
null/JJ
distribution/NN
,/,
respectively/RB
./.
====================
s/NNS
G/NN
I/NN
D/NN
S/NN
=/JJ
G/NN
I/NN
D/NN
S/NN
-/:
G/NN
I/NN
D/NN
S/NN
¯/CD
S/NN
G/NN
I/NN
D/NN
S/NN
(/(
3/CD
)/)
====================
Association/NN
strengths/NNS
from/IN
different/JJ
orders/NNS
of/IN
gene-gene/NN
interactions/NNS
may/MD
be/VB
compared/VBN
using/VBG
the/DT
standardized/VBN
GIDS/NN
(/(
sGIDS/NNS
)/)
,/,
defined/VBN
above/JJ
[/(
10/CD
]/)
./.
====================
Analysis/NN
====================
Construction/NN
of/IN
multi-class/JJ
phenotype/NN
====================
Among/IN
the/DT
procedures/NNS
to/TO
measure/VB
blood/NN
glucose/NN
levels/NNS
,/,
fasting/VBG
and/CC
the/DT
oral/JJ
glucose/NN
tolerance/NN
test/NN
(/(
OGTT/NN
)/)
are/VBP
commonly/RB
conducted/VBN
[/(
1112/CD
]/)
./.
====================
Standard/JJ
time/NN
intervals/NNS
between/IN
the/DT
intake/JJ
and/CC
measurement/NN
are/VBP
1/CD
h/NN
and/CC
2/CD
h/NN
,/,
denoted/VBN
as/IN
OGTT-1h/JJ
and/CC
OGTT-2h/JJ
[/(
7/CD
]/)
./.
====================
Diagnostic/JJ
criteria/NNS
are/VBP
recommended/VBN
as/IN
a/DT
combination/NN
of/IN
the/DT
measurements/NNS
[/(
6/CD
]/)
./.
====================
Listed/JJ
in/IN
Table/JJ
1/CD
,/,
the/DT
diagnosis/NN
is/VBZ
determined/VBN
by/IN
considering/VBG
fasting/JJ
and/CC
OGTT-2h/JJ
simultaneously/RB
[/(
7/CD
]/)
./.
====================
Each/DT
of/IN
them/PRP
was/VBD
categorized/VBN
into/IN
3/CD
distinct/JJ
ranges/NNS
,/,
resulting/VBG
in/IN
9/CD
composite/JJ
ranges/VBZ
,/,
which/WDT
gave/VBD
the/DT
criteria/NNS
for/IN
the/DT
4/CD
diagnostic/JJ
categories/NNS
./.
====================
Genomic/JJ
data/NNS
from/IN
the/DT
Korean/JJ
Association/NN
Resource/NN
(/(
KARE/NN
)/)
project/VBP
[/(
13/CD
]/)
were/VBD
analyzed/VBN
with/IN
the/DT
phenotypes/NNS
of/IN
fasting/JJ
and/CC
OGTT-2h/JJ
and/CC
-1h/JJ
./.
====================
With/IN
the/DT
number/NN
of/IN
valid/JJ
samples/NNS
(/(
n/NN
=/JJ
8371/CD
)/)
,/,
the/DT
proportions/NNS
that/DT
fell/JJ
into/IN
each/DT
of/IN
the/DT
9/CD
composite/JJ
categories/NNS
are/VBP
shown/VBN
in/IN
the/DT
fourth/JJ
column/NN
of/IN
Table/JJ
1/CD
./.
====================
Note/RB
that/DT
neither/CC
of/IN
fasting/JJ
and/CC
OGTT-2h/JJ
can/MD
determine/VB
the/DT
diagnostic/JJ
result/NN
independently/RB
of/IN
each/DT
other/JJ
./.
====================
An/DT
additional/JJ
diagnostic/JJ
criterion/NN
may/MD
be/VB
given/VBN
by/IN
OGTT-1h/JJ
[/(
7/CD
]/)
./.
====================
The/DT
last/JJ
column/NN
of/IN
Table/JJ
1/CD
shows/VBZ
the/DT
percentage/NN
of/IN
the/DT
samples/NNS
that/DT
were/VBD
found/VBN
to/TO
be/VB
normal/JJ
in/IN
OGTT-1h/JJ
within/IN
each/DT
of/IN
the/DT
9/CD
composite/JJ
categories/NNS
./.
====================
A/DT
need/JJ
for/IN
additional/JJ
categorization/NN
seems/VBZ
to/TO
be/VB
apparent/JJ
,/,
because/IN
most/JJS
of/IN
the/DT
percentages/NNS
are/VBP
away/NN
from/IN
0/CD
%/NN
or/CC
100/CD
%/NN
./.
====================
To/TO
make/VB
such/JJ
a/DT
multi-class/JJ
phenotype/NN
,/,
3/CD
of/IN
the/DT
individual/JJ
KARE/NN
phenotypes—fasting/VBG
,/,
OGTT-2h/NNP
,/,
and/CC
OGTT-1h—were/JJ
first/JJ
categorized/VBD
into/IN
3/CD
classes/NNS
for/IN
the/DT
first/JJ
2/CD
phenotypes/NNS
and/CC
into/IN
2/CD
classes/NNS
for/IN
the/DT
third/JJ
one/CD
,/,
following/VBG
the/DT
reference/NN
criteria/NNS
[/(
67/CD
]/)
./.
====================
A/DT
single/JJ
composite/JJ
phenotype/NN
of/IN
3×3×2/CD
classes/NNS
was/VBD
constructed/VBN
as/IN
such/JJ
./.
====================
The/DT
resulting/VBG
18-class/CD
composite/JJ
phenotype/NN
was/VBD
analysed/VBN
with/IN
the/DT
genotype/NN
part/NN
using/VBG
GIDS/NN
to/TO
identify/VB
the/DT
most/JJS
associated/VBN
single-/JJ
and/CC
two-locus/JJ
models/NNS
./.
====================
Single-/NN
and/CC
two-locus/JJ
models/NNS
====================
All/DT
of/IN
the/DT
available/JJ
327,872/CD
SNPs/NNS
in/IN
the/DT
KARE/NN
dataset/NN
were/VBD
thoroughly/RB
examined/VBN
for/IN
the/DT
association/NN
with/IN
the/DT
multi-class/JJ
phenotype/NN
constructed/VBN
above/JJ
./.
====================
Ranked/JJ
by/IN
the/DT
sGIDS/NN
,/,
the/DT
top/NN
50/CD
SNPs/NNS
are/VBP
plotted/VBN
in/IN
Fig/NN
./.
====================
2/CD
,/,
representing/VBG
the/DT
main/JJ
effects/NNS
./.
====================
Prominent/JJ
SNPs/NNS
may/MD
be/VB
seen/VBN
in/IN
groups/NNS
of/IN
2/CD
,/,
2/CD
,/,
and/CC
4/CD
showing/VBG
the/DT
strongest/JJS
association/NN
strengths/NNS
./.
====================
Those/DT
SNPs/NNS
are/VBP
listed/VBN
in/IN
Table/JJ
2/CD
with/IN
detailed/JJ
information/NN
./.
====================
Using/VBG
the/DT
calculations/NNS
for/IN
the/DT
single-locus/JJ
model/NN
,/,
1,000/CD
SNPs/NNS
were/VBD
selected/VBN
by/IN
sorting/VBG
them/PRP
with/IN
their/PRP$
respective/JJ
GIDS/NN
values/NNS
./.
====================
Then/RB
,/,
all/DT
of/IN
the/DT
possible/JJ
pairs/NNS
of/IN
those/DT
candidate/NN
SNPs/NNS
were/VBD
examined/VBN
for/IN
their/PRP$
association/NN
strengths/NNS
by/IN
evaluating/VBG
sGIDS/NN
./.
====================
The/DT
50/CD
most/JJS
strongly/RB
associated/VBN
pairs/NNS
are/VBP
plotted/VBN
in/IN
Fig/NN
./.
====================
3/CD
,/,
5/CD
of/IN
which/WDT
are/VBP
identified/VBN
with/IN
their/PRP$
rs/NNS
numbers/NNS
./.
====================
Two/CD
SNPs/NNS
,/,
rs7747752/NN
and/CC
rs7767391/NN
,/,
were/VBD
found/VBN
to/TO
have/VB
the/DT
strongest/JJS
association/NN
./.
====================
They/PRP
are/VBP
located/JJ
in/IN
an/DT
intron/NN
of/IN
the/DT
cyclin-dependent-like/JJ
kinase/NN
5/CD
(/(
CDK5/NN
)/)
regulatory/JJ
subunit/NN
associated/VBN
protein/NN
1-like/JJ
1/CD
(/(
CDKAL1/NN
)/)
gene/NN
located/JJ
in/IN
chromosome/NN
6/CD
./.
====================
This/DT
gene/NN
has/VBZ
been/VBN
reported/VBN
to/TO
make/VB
contributions/NNS
to/TO
type/NN
II/CD
diabetes/NNS
./.
====================
Both/DT
of/IN
the/DT
SNPs/NNS
identified/VBN
in/IN
this/DT
paper/NN
have/VBP
been/VBN
also/RB
reported/VBD
to/TO
have/VB
susceptibility/NN
to/TO
type/NN
II/CD
diabetes/NNS
[/(
14151617/CD
]/)
./.
====================
Note/RB
that/DT
among/IN
the/DT
second-tier/NN
SNPs—rs2328549/NN
and/CC
rs17487711—only/RB
the/DT
first/JJ
one/CD
is/VBZ
in/IN
the/DT
intron/NN
of/IN
CDKAL1/NN
[/(
18/CD
]/)
./.
====================
rs17487711/NN
has/VBZ
been/VBN
newly/RB
identified/VBN
to/TO
have/VB
strong/JJ
association/NN
comparable/JJ
with/IN
that/DT
of/IN
rs2328549/NN
,/,
while/IN
it/PRP
is/VBZ
located/JJ
in/IN
the/DT
intron/NN
of/IN
LOC-105379297/NN
in/IN
chromosome/NN
8/CD
./.
====================
The/DT
National/JJ
Center/NN
for/IN
Biotechnology/NN
Information/NN
(/(
NCBI/NN
)/)
still/RB
describes/VBZ
this/DT
gene/NN
as/IN
uncharacterized/JJ
./.
====================
In/IN
Table/JJ
2/CD
,/,
3/CD
out/RB
of/IN
4/CD
among/IN
third-tier/DT
SNPS/NN
have/VBP
been/VBN
listed/VBN
to/TO
be/VB
in/IN
the/DT
intron/NN
of/IN
ATPase/NN
,/,
class/NN
II/CD
,/,
type/NN
9B/CD
(/(
ATP9B/NN
)/)
located/JJ
in/IN
chromosome/NN
18/CD
[/(
19/CD
]/)
,/,
whereas/IN
rs9465871/NN
can/MD
be/VB
found/VBN
in/IN
the/DT
intron/NN
of/IN
CDKAL1/NN
[/(
202122/CD
]/)
./.
====================
A/DT
single/JJ
prominent/JJ
pair/NN
(/(
rs2328549/NN
,/,
rs6486740/NN
)/)
revealed/VBD
itself/PRP
./.
====================
In/IN
Table/JJ
3/CD
,/,
detailed/JJ
information/NN
is/VBZ
provided/VBN
for/IN
the/DT
top/NN
5/CD
pairs/NNS
./.
====================
One/CD
of/IN
the/DT
SNPs/NNS
in/IN
the/DT
pair/NN
that/DT
showed/VBD
the/DT
strongest/JJS
association/NN
,/,
rs6486740/RB
,/,
is/VBZ
located/JJ
in/IN
an/DT
intron/NN
of/IN
the/DT
glycosyltransferase/NN
1/CD
domain-containing/JJ
1/CD
(/(
GLT1D1/NN
)/)
gene/NN
on/IN
chromosome/NN
12/CD
,/,
while/IN
the/DT
other/JJ
SNP/NN
,/,
rs2328549/NN
,/,
is/VBZ
located/JJ
in/IN
an/DT
intron/NN
of/IN
CDKAL1/NN
,/,
which/WDT
was/VBD
mentioned/VBN
in/IN
the/DT
previous/JJ
subsection/NN
./.
====================
GLT1D1/NN
was/VBD
reported/VBN
to/TO
be/VB
related/JJ
with/IN
renal/JJ
sinus/NN
fat/NN
[/(
23/CD
]/)
and/CC
the/DT
transfers/NNS
of/IN
glycosyl/NN
groups/NNS
[/(
24/CD
]/)
./.
====================
Among/IN
the/DT
second-tier/NN
SNP/NN
pairs/NNS
,/,
rs7029094/NN
and/CC
rs1995761/NN
are/VBP
located/JJ
on/IN
chromosome/NN
9/CD
,/,
but/CC
there/EX
exists/VBZ
little/JJ
information/NN
about/IN
the/DT
gene/NN
in/IN
which/WDT
they/PRP
are/VBP
located/JJ
./.
====================
A/DT
composite/JJ
trait/VBP
of/IN
18/CD
classes/NNS
,/,
constructed/VBN
with/IN
3/CD
observables/NNS
,/,
each/DT
of/IN
which/WDT
had/VBD
3/CD
or/CC
2/CD
classes/NNS
,/,
was/VBD
analyzed/VBN
with/IN
genomic/JJ
data/NNS
to/TO
estimate/VB
the/DT
genome-wide/NN
association/NN
./.
====================
Gene-gene/NN
interactions/NNS
,/,
as/IN
well/RB
as/IN
the/DT
main/JJ
effect/NN
,/,
were/VBD
investigated/VBN
./.
====================
It/PRP
may/MD
be/VB
essential/JJ
to/TO
take/VB
a/DT
multi-class/JJ
composite/JJ
phenotype/NN
into/IN
consideration/NN
when/WRB
performing/VBG
a/DT
genomic/JJ
association/NN
study/NN
for/IN
the/DT
susceptibility/NN
to/TO
a/DT
more/RBR
complex/NN
disease/NN
,/,
such/JJ
as/IN
diabetes/NNS
,/,
as/IN
presented/VBN
in/IN
this/DT
paper/NN
./.
====================
OGTT-2h/DT
alone/RB
has/VBZ
3/CD
categories/NNS
that/DT
exceed/VBP
the/DT
commonly/RB
used/VBN
dichotomous/JJ
classes/NNS
./.
====================
However/RB
,/,
the/DT
intrinsic/JJ
need/VBD
of/IN
a/DT
composite/JJ
phenotype/NN
comes/NNS
from/IN
the/DT
fact/NN
that/IN
diabetes/VBZ
may/MD
not/RB
be/VB
fully/RB
diagnosed/VBN
with/IN
a/DT
single/JJ
observable/JJ
./.
====================
If/IN
a/DT
disease/NN
may/MD
be/VB
diagnosed/VBN
by/IN
multiple/JJ
variables/NNS
,/,
it/PRP
would/MD
be/VB
logical/JJ
to/TO
analyze/VB
the/DT
susceptibility/NN
to/TO
it/PRP
with/IN
multiple/JJ
observables/NNS
concurrently/RB
./.
====================
A/DT
composite/JJ
phenotype/NN
can/MD
be/VB
expected/VBN
to/TO
have/VB
many/JJ
classes/NNS
,/,
and/CC
the/DT
number/NN
of/IN
them/PRP
could/MD
grow/VB
rapidly/RB
as/IN
the/DT
number/NN
of/IN
required/VBN
variables/NNS
increases/VBZ
./.
====================
Therefore/RB
,/,
it/PRP
would/MD
be/VB
essential/JJ
to/TO
have/VB
a/DT
methodology/NN
capable/JJ
of/IN
analyzing/VBG
the/DT
genomic/JJ
association/NN
with/IN
a/DT
phenotype/NN
having/VBG
an/DT
indefinite/JJ
number/NN
of/IN
classes/NNS
./.
====================
GIDS/NN
has/VBZ
been/VBN
demonstrated/VBN
,/,
in/IN
this/DT
paper/NN
,/,
as/IN
a/DT
reliable/JJ
candidate/NN
for/IN
this/DT
purpose/NN
./.
====================
It/PRP
showed/VBD
consistency/NN
by/IN
identifying/VBG
strongly/RB
associated/VBN
SNPs/NNS
,/,
in/IN
chromosome/NN
6/CD
,/,
agreeing/VBG
with/IN
previously/RB
reported/VBD
ones/NNS
in/IN
a/DT
single-locus/JJ
model/NN
./.
====================
The/DT
CDKAL1/NN
gene/NN
,/,
in/IN
which/WDT
they/PRP
are/VBP
located/JJ
,/,
has/VBZ
been/VBN
found/VBN
to/TO
be/VB
responsible/JJ
for/IN
the/DT
SNPs/NNS
that/DT
cause/VBP
the/DT
susceptibility/NN
to/TO
type/NN
II/CD
diabetes/NNS
./.
====================
Moreover/RB
,/,
we/PRP
found/VBD
new/JJ
SNPs/NNS
that/DT
have/VBP
not/RB
been/VBN
reported/VBN
to/TO
have/VB
a/DT
strong/JJ
association/NN
./.
====================
They/PRP
were/VBD
found/VBN
in/IN
chromosomes/NNS
8/CD
and/CC
18/CD
./.
====================
The/DT
gene-gene/NN
interaction/NN
result/NN
detected/VBN
a/DT
single/JJ
prominent/JJ
SNP/NN
pair/NN
that/DT
was/VBD
noticeably/RB
stronger/JJR
than/IN
others/NNS
./.
====================
Although/IN
1/CD
of/IN
the/DT
2/CD
SNPs/NNS
in/IN
that/DT
pair/NN
,/,
rs6486740/CD
in/IN
the/DT
GLT1D1/NN
gene/NN
,/,
was/VBD
not/RB
found/VBN
to/TO
have/VB
a/DT
strong/JJ
main/JJ
effect/NN
,/,
it/PRP
showed/VBD
a/DT
very/RB
strong/JJ
association/NN
when/WRB
it/PRP
interacted/VBD
with/IN
the/DT
counterpart/NN
SNP/NN
,/,
rs2328549/NN
./.
====================
In/IN
summary/NN
,/,
we/PRP
have/VBP
confirmed/VBN
previous/JJ
results/NNS
and/CC
at/IN
the/DT
same/JJ
time/NN
found/VBN
new/JJ
strong/JJ
genomic/JJ
associations/NNS
in/IN
both/DT
single-/JJ
and/CC
2-locus/FW
models/NNS
by/IN
applying/VBG
GIDS/NN
to/TO
a/DT
composite/JJ
trait/VBP
with/IN
18/CD
classes/NNS
./.
====================
Schematics/NNS
for/IN
the/DT
2-order/JJ
genegene/NN
interaction/NN
and/CC
multi-class/JJ
phenotype/NN
./.
====================
The/DT
number/NN
of/IN
samples/NNS
,/,
nij/CD
,/,
for/IN
a/DT
genotypic/JJ
class/NN
i/LS
and/CC
phenotypic/JJ
class/NN
j/CD
./.
====================
When/WRB
J/NN
=/JJ
2/CD
,/,
it/PRP
represents/VBZ
the/DT
common/JJ
binary/NN
,/,
or/CC
case-control/JJ
trait/NN
./.
====================
Most/JJS
strongly/RB
associated/VBN
single-nucleotide/JJ
polymorphisms/NNS
identified/VBN
by/IN
sGIDS/NN
./.
====================
sGIDS/NNS
reveals/VBZ
strongly/RB
associated/VBN
single/JJ
loci/NNS
with/IN
fasting/JJ
,/,
OGTT-1h/NNP
,/,
and/CC
OGTT-2h/JJ
blood/NN
glucose/NN
values/NNS
categorized/VBD
as/IN
a/DT
single/JJ
multi-class/JJ
phenotype/NN
./.
====================
sGIDS/NNS
,/,
standardized/VBD
generalized/VBN
index/NN
of/IN
dissimilarity/NN
;/:
OGTT-1h/RB
,/,
1-hour/CD
oral/JJ
glucose/NN
tolerance/NN
test/NN
;/:
OGTT-2h/RB
,/,
2-hour/CD
oral/JJ
glucose/NN
tolerance/NN
test/NN
./.
====================
Most/JJS
strongly/RB
associated/VBN
single-nucleotide/JJ
polymorphism/NN
pairs/NNS
identified/VBN
by/IN
sGIDS/NN
./.
====================
sGIDS/NNS
reveals/VBZ
strongly/RB
associated/VBN
2-order/JJR
interactions/NNS
between/IN
2/CD
loci/NNS
with/IN
fasting/JJ
,/,
OGTT-1h/NNP
,/,
and/CC
OGTT-2h/JJ
blood/NN
glucose/NN
values/NNS
categorized/VBD
as/IN
a/DT
single/JJ
multi-class/JJ
phenotype/NN
./.
====================
sGIDS/NNS
,/,
standardized/VBD
generalized/VBN
index/NN
of/IN
dissimilarity/NN
;/:
OGTT-1h/RB
,/,
1-hour/CD
oral/JJ
glucose/NN
tolerance/NN
test/NN
;/:
OGTT-2h/RB
,/,
2-hour/CD
oral/JJ
glucose/NN
tolerance/NN
test/NN
./.
====================
OGTT/NN
criteria/NNS
[/(
67/CD
]/)
with/IN
KARE/NN
[/(
13/CD
]/)
result/NN
====================
Top/RB
associated/VBN
SNPs/NNS
by/IN
sGIDS/NN
in/IN
the/DT
single-locus/JJ
model/NN
====================
Top/RB
associated/VBN
interacting/VBG
SNP/NN
pairs/NNS
by/IN
sGIDS/NN
in/IN
the/DT
2-locus/JJ
model/NN
====================
